Heidi Kraus
About Heidi Kraus
Heidi Kraus serves as the Vice President of Intellectual Property at EyePoint Pharmaceuticals, a position she has held since 2021. She has extensive experience in the field, having previously worked at Teva Pharmaceuticals, Abon Pharmaceuticals LLC, and Sterne, Kessler, Goldstein & Fox.
Work at EyePoint Pharmaceuticals
Heidi Kraus serves as the Vice President of Intellectual Property at EyePoint Pharmaceuticals. She has held this position since 2021 and has contributed to the company's strategic initiatives in intellectual property management for three years. Her role involves overseeing the development and protection of the company's intellectual assets, ensuring compliance with relevant regulations, and supporting the company's innovation efforts.
Previous Experience at Teva Pharmaceuticals
Before joining EyePoint Pharmaceuticals, Heidi Kraus worked at Teva Pharmaceuticals as Executive IP Counsel for a period of ten months in 2009. In this role, she was responsible for managing intellectual property matters, providing legal guidance, and supporting the company's objectives in the pharmaceutical sector.
Previous Role at Abon Pharmaceuticals LLC
Heidi Kraus served as General Counsel at Abon Pharmaceuticals LLC from 2011 to 2013. During her two-year tenure, she managed the legal affairs of the company, focusing on intellectual property and regulatory compliance, which are critical in the pharmaceutical industry.
Career at Sterne, Kessler, Goldstein & Fox
Heidi Kraus was a Partner at Sterne, Kessler, Goldstein & Fox from 1997 to 2006. Over her nine years at the firm, she specialized in intellectual property law, providing legal counsel and representation to clients in various sectors, including pharmaceuticals and biotechnology.
Education and Expertise
Heidi Kraus obtained her Juris Doctor (JD) degree from The George Washington University Law School, where she studied from 1994 to 1997. Her education has equipped her with a strong foundation in law, particularly in intellectual property, which she has applied throughout her career in the pharmaceutical industry.